ELAVL4 and neuroblastoma: One promising therapeutic target is the HuD antigen, a neuronal-specific RNA binding protein that is highly expressed in both NB and SCLC cells and was shown to promote NB tumor growth and survival through suppressing apoptotic pathways and downregulating mTORC1 activity (59).